New data regarding the prevalence of Alzheimer's disease is looming far and above previous estimates: 17 percent higher than previously thought, according to statistics from Alzheimer's Disease International.

Human nature being what it is, physician participation in Medicare’s Physician Quality Reporting System (PQRS) will likely accelerate as the agency phases incentives out and penalties in. The effect may prove especially conspicuous since the bonuses have been voluntary and modest. By contrast, the forfeitures will be automatic and, if paired with other pay-for-performance requirements, impossible to ignore.

Painful rejection and other social ills prompt the same opioid response in the brain as physical pain, according to new in vivo PET neuroimaigng of snubbed subjects. 

Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.

With increasing prevalence of Alzheimer’s disease threatening to bankrupt Medicare and Medicaid by 2050, the fiscal pinch of the sequester could extend decades into the future and compromise already-limited progress on Alzheimer’s disease prevention and treatment. A letter in the New York Times detailed the data.

A team of radiologists and neurologists at University Hospitals Case Medical Center in Cleveland are enrolling patients with suspected early-stage Alzheimer’s disease in a study designed to determine if Amyvid can identify amyloid plaques via PET or MRI. Read more about the research by clicking the link below.

Baxter announced results of its Phase III clinical study of immunoglobulin (IG). In the randomized, double-blind, placebo-controlled, multi-center trial, IG did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease after 18 months of treatment. Given the findings, Baxter said it will re-evaluate its approach for its Alzheimer’s program.

Eli Lilly and Company has acquired a pair of PET tracers from Siemens. The investigational tracers are designed to target the tau deposits that are the hallmark of Alzheimer’s disease. Avid Radiopharmaceuticals, Lilly’s wholly owned subsidiary, will develop and validate the tracers, according to Lilly.